Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 

Longer dual anti-HER2 therapy may improve response in HER2+ breast cancer

16 Mar 2020

A 24-week course of dual anti-HER2 treatment produces a numeric increase in response rates compared with a 12-week course without using chemotherapy in women with breast cancer harbouring a HER2 mutation, according to the results of a phase II trial.

The trial combined a Simon phase II design in the experimental arm with a pick-the-winner design. A total of 97 women with HER2-positive breast tumours measuring ≥2 cm (median, 5 cm) were randomly assigned to receive 12 (n=33) or 24 weeks (n=24) of lapatinib plus trastuzumab.

In patients whose tumours were also oestrogen receptor (ER)-positive, letrozole (along with ovarian suppression if premenopausal) was administered. All evaluable patients were assessed for in-breast pathologic complete response (pCR).

Of the patients, 94 were evaluable. The median age of the cohort was 51 years, and 55 percent were postmenopausal. Median tumour size was 5 cm, and 65 percent were ER-positive. The longer treatment arm showed superiority over the shorter arm in terms of the rate of pCR (28 percent vs 12 percent). The increased response observed with the 24-week course was driven by an increased pCR in the ER-positive subgroup (33 percent vs 9 percent).

Treatment was well tolerated, with grade 1–2 diarrhoea and acneiform rash being the most common toxicities.

The findings, if validated, may help identify patients who may benefit from de-escalation of therapy, researchers said.


 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting.